Our results showed few women (2.4%) with T1D were receiving continuous subcutaneous insulin infusions (CSII) in comparison with those in the United Kingdom (20%) [33, 34], which could be due to its out of pocket cost in Australia and HCP time requirements [35].A range of barriers have been identified, similar to those reported previously [36], that are likely to have contributed to limitations in clinical care and self-management. Here, INS is linked to type 1 diabetes mellitus.